Latest Breaking News On - Annm hanly - Page 3 : comparemela.com

Vir Biotechnology (NASDAQ:VIR) Shares Down 2 7% After Insider Selling

Vir Biotechnology (NASDAQ:VIR) Shares Down 2 7% After Insider Selling
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Annm hanlyQuadrant capital groupVir biotechnology incChina universal asset management coThird bancorpJpmorgan chase coFifth third bancorpVir biotechnologyGet free reportCapital groupUniversal asset managementCaptrust financial advisorsFinancial advisorsVir biotechnology daily

Vir Biotechnology, Inc (NASDAQ:VIR) EVP Sells $123,574 80 in Stock

Vir Biotechnology, Inc (NASDAQ:VIR) EVP Sells $123,574 80 in Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Annm hanlyMetlife investment managementNeedham companyJpmorgan chase coBlackrock incAcadian asset managementVir biotechnology incDimensional fund advisorsVir biotechnologyGet free reportAsset managementLife investment managementFund advisorsVir biotechnology daily

Profund Advisors LLC Has $853,000 Position in Vir Biotechnology, Inc (NASDAQ:VIR)

Profund Advisors LLC grew its stake in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 51.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 91,038 shares of the company’s stock after acquiring an additional 31,029 shares during the quarter. Profund […]

Annm hanlyGeorgea scangosChina universal asset management coProfund advisorsCm bidwell associates ltdExchange commissionFifth third bancorpNeedham companySecurities exchange commissionJpmorgan chase coVir biotechnology incThird bancorpVir biotechnologyFree reportUniversal asset managementFinancial advisors

Vir Biotechnology, Inc (NASDAQ:VIR) Given Consensus Recommendation of Moderate Buy by Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) has been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price […]

Annm hanlySecurities exchange commissionEndurance cayman ltd svfMorgan stanleyBlackrock incNeedham companyVanguard group incRenaissance technologiesPacer advisors incJpmorgan chase coVir biotechnology incVir biotechnologyGet ratingLtd svfExchange commissionStreet corp

Vir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Misses Expectations By $0 20 EPS

Vir Biotechnology (NASDAQ:VIR – Get Rating) posted its quarterly earnings results on Thursday. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.20), Briefing.com reports. The business had revenue of $63.00 million for the quarter, compared to analyst estimates of $50.10 million. The firm’s quarterly revenue was down 94.9% […]

Annm hanlyVir biotechnology company profileNeedham companySecurities exchange commissionEndurance cayman ltd svfBlackrock incJpmorgan chase coGeode capital managementVanguard group incVir biotechnology incVir biotechnologyGet ratingLtd svfExchange commissionStreet corpCapital management